Durata Therapeutics Inc  

(Public, NASDAQ:DRTX)   Watch this stock  
Find more results for DRTX
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.76
Shares 26.79M
Beta     -
Inst. own 92%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -199.30% -
Operating margin -181.17% -
EBITD margin - -
Return on average assets -99.75% -66.57%
Return on average equity - -150.73%
Employees 68 -
CDP Score - -


200 S Wacker Dr Ste 2550
CHICAGO, IL 60606-5811
United States - Map
+1-312-2197000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. The product achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.